8-K: Enhabit Q2 2025 Results: Strong Growth, Raised Guidance

Enhabit, Inc. reports strong second quarter 2025 financial results with sequential and year-over-year growth in revenue and Adjusted EBITDA, leading to increased full-year guidance.

Summary

• Consolidated net service revenue reached $266.1 million, an increase of 2.1% year-over-year and 2.4% sequentially.
• Adjusted EBITDA grew 6.7% year-over-year and 1.2% sequentially to $26.9 million.
• Net income attributable to Enhabit, Inc. was $5.2 million, a significant improvement from a $0.2 million loss in Q2 2024.
• Adjusted diluted earnings per share increased 85.7% to $0.13 from $0.07 in Q2 2024.
• Home health non-Medicare admissions increased 5.2% year-over-year, with total admissions growing 1.3% (2.0% when normalized for closed branches).
• Hospice average daily census (ADC) rose 12.3% year-over-year, marking its sixth consecutive quarter of growth, and admissions increased 8.7% (10.0% normalized).
• The company reduced bank debt by $10.0 million in the quarter, contributing to $45 million in prepayments since Q1 2024, which lowered interest expense by $3.2 million over the same period.
• Three de novo locations were opened in Q2 2025 (one home health, two hospice), bringing the year-to-date total to four, on track for a goal of 10 in 2025.
• Full-year 2025 guidance was increased for Net Service Revenue to $1,060 million to $1,073 million, Adjusted EBITDA to $104 million to $108 million, and Adjusted EPS to $0.47 to $0.55.

Sentiment

Score: 8

Explanation: The company reported strong Q2 results with significant year-over-year improvements in key financial metrics like net income and Adjusted EPS. It also raised its full-year guidance, indicating confidence in future performance. Consistent debt reduction and strategic growth initiatives (de novo locations, payer contracts) are positive indicators, despite some segment-specific declines in home health Medicare volumes.

Positives

• Consolidated net service revenue grew 2.1% year-over-year and 2.4% sequentially to $266.1 million.
• Consolidated Adjusted EBITDA grew 6.7% year-over-year and 1.2% sequentially to $26.9 million.
• Net income attributable to Enhabit, Inc. was $5.2 million, a significant improvement from a $0.2 million loss in Q2 2024.
• Adjusted diluted EPS increased 85.7% to $0.13 from $0.07 in Q2 2024.
• Home health non-Medicare admissions increased 5.2% year-over-year.
• Home health total admissions grew 1.3% year-over-year (2.0% normalized for closed branches).
• Home health achieved its second straight quarter of net service revenue and Adjusted EBITDA growth.
• Home health Medicare average daily census (ADC) showed further stabilization.
• Hospice ADC increased 12.3% year-over-year, marking its sixth consecutive quarter of growth.
• Hospice admissions increased 8.7% year-over-year (10.0% normalized for closed branches).
• Hospice Adjusted EBITDA increased 53.8% year-over-year.
• Consistent de-levering of the balance sheet with the fifth straight quarter of debt prepayment, reducing bank debt by $10.0 million in the quarter and $45 million since Q1 2024.
• Debt prepayments lowered interest expense by $3.2 million over the same period (since Q1 2024).
• Opened three de novo locations in Q2 2025 (one home health, two hospice), on track for a goal of 10 in 2025.
• Increased full-year 2025 guidance for Net Service Revenue, Adjusted EBITDA, and Adjusted EPS.
• Home health successfully re-negotiated a national payer agreement resulting in a low double-digit percentage rate increase.
• Home health cost per patient day remained flat year-over-year due to staffing optimization offsetting market inflation.
• Hospice cost per patient day increased only 1.0% year-over-year, with improved clinical productivity offsetting market-related inflation impacts.
• Quality of Patient Care (QoPC) Star Rating of 3.1, with 67% of home health agencies at 3 Stars or higher and 21% at 4 Stars or higher.
• Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Star Rating of 4.0, with 99% of home health agencies at 3 Stars or higher and 80% at 4 Stars or higher.
• 30-Day Hospital Readmission Rate of 14.1%, significantly better than the national average of 18.0%.
• Patient Visits in Last Days of Life for Hospice at 67.1%, significantly better than the national average of 47.4%.

Negatives

• Home health net service revenue decreased 2.0% year-over-year to $205.9 million.
• Home health Medicare admissions decreased 3.7% year-over-year.
• Home health Medicare average daily census decreased 3.4% year-over-year.
• Home health Segment Adjusted EBITDA decreased 11.1% year-over-year to $39.3 million.
• Home health revenue per patient day decreased 2.5% year-over-year.
• Home health cost per visit increased 6.4% year-over-year to $94.7.
• Consolidated gross margin decreased to 49.1% from 49.4% year-over-year.
• Home health gross margin decreased to 47.9% from 49.1% year-over-year.
• Hospice discharged average length of stay decreased 4.6% year-over-year to 103 days.

Risks

• Ability to execute on strategic plans.
• Regulatory and other developments impacting the markets for services.
• Changes in reimbursement rates.
• General economic conditions.
• Changes in the episodic versus non-episodic mix of payers, patient case mix, and payment methodologies.
• Ability to attract and retain key management personnel and healthcare professionals.
• Potential disruptions or breaches of information systems (Company, vendors, payers, contract counterparties).
• Outcome of litigation.
• Quality performance and ratings.
• Ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures.
• Ability to successfully integrate technology in operations.
• Ability to control costs, particularly labor and employee benefit costs.

Future Outlook

The company increased its full-year 2025 guidance for Net Service Revenue to $1,060 million to $1,073 million, Adjusted EBITDA to $104 million to $108 million, and Adjusted EPS to $0.47 to $0.55. This reflects confidence in continued momentum, particularly in hospice growth and home health stabilization, alongside ongoing debt reduction efforts and strategic de novo location openings.

Management Comments

• Our second quarter results reflect strong execution of our strategic 2025 priorities, with sequential and year-over-year growth in revenue and Adjusted EBITDA.
• Home health continued to benefit from our payer contract initiatives as admissions grew 1.3% year over year and saw further stabilization in Medicare Fee-for-Service census.
• Hospice delivered its sixth consecutive quarter of growth with average daily census rising 12.3% year over year.
• We also strengthened our balance sheet by reducing bank debt and increasing liquidity. With this momentum, we're well positioned for success in the second half of 2025.

Industry Context

The results align with broader healthcare trends favoring in-home care, driven by an aging population and the cost-efficiency of home health and hospice services. The company's focus on payer contract initiatives and de novo growth positions it to capitalize on the growing addressable markets, which are projected to reach approximately $41 billion for Medicare skilled home health and $32 billion for Medicare Hospice expenditures by 2028. The company's ability to deliver care at a significantly lower cost (e.g., $63/day for home health vs. $556/day for SNF) supports its strategic advantage in the evolving healthcare landscape.

Comparison to Industry Standards

• Enhabit's Quality of Patient Care (QoPC) Star Rating is 3.1, which is better than the national average of 3.0 (as of July 16, 2025).
• Enhabit's Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Star Rating is 4.0, which is better than the national average of 3.7 (as of July 16, 2025).
• Enhabit's 30-Day Hospital Readmission Rate is 14.1%, which is 21.7% better than the national average of 18.0% (Research Institute for Home Care 2024 Chartbook).
• Enhabit's Hospice Patient Visits in Last Days of Life is 67.1%, which is 41.6% better than the national average of 47.4% (Medicare fee for service claims data).
• Enhabit's Home Health cost per patient day is $28.0, significantly lower than the average Medicare cost per day for Skilled Nursing Facilities (SNF) at $556 and Hospice at $186, demonstrating superior cost efficiency in the post-acute service sector.

Legal Proceedings

• Unusual or nonrecurring items in Q2 2025 include costs associated with nonroutine litigation.
• Unusual or nonrecurring items in Q2 2024 include costs associated with nonroutine litigation.

Stakeholder Impact

• Shareholders: Positive impact due to increased net income, Adjusted EPS, raised guidance, and consistent debt reduction, potentially leading to increased share value.
• Employees: Positive impact from continued growth and expansion (de novo locations), suggesting job stability and potential for new opportunities. Staffing optimization mentioned, which could imply efficiency focus.
• Customers (Patients/Families): Positive impact from high-quality outcomes (e.g., high star ratings, lower readmission rates, increased visits in last days of life) and expansion of services through de novo locations.
• Payer/Creditors: Positive impact from improved financial health, consistent debt reduction, and successful renegotiation of payer contracts, indicating a more reliable partner.

Next Steps

• Host an investor conference call on August 7, 2025, at 10 a.m. EDT to discuss Q2 2025 results.
• Continue to open de novo locations, with a goal of 10 in 2025.
• Continue de-levering the balance sheet.
• Focus on home health census, payer mix, and hospice average daily census growth.
• Optimize de novo locations opened in 2023 and 2024.
• Manage General and Administrative (G&A) expenses and control cost per patient day.
• Improve value-based performance, patient and family experience, home health hospital readmission rates, and hospice visits in the last days of life.
• Focus on engagement, retention, business development direct selling headcount, and leadership development.

Key Dates

Recommendation

The company demonstrated strong financial performance in Q2 2025, significantly improving net income and Adjusted EPS year-over-year. The increase in full-year guidance for revenue, Adjusted EBITDA, and Adjusted EPS signals robust confidence in future growth. Strategic initiatives like consistent debt reduction, successful payer contract renegotiations, and expansion through de novo locations are effectively strengthening the balance sheet and driving operational efficiency. The company's superior quality outcomes and cost-effectiveness in the growing home health and hospice markets further solidify its competitive position, making it an attractive investment.

Keywords

Home Health, Hospice, Healthcare Services, Post-Acute Care, Patient Care, EBITDA, Revenue Growth, Debt Reduction, SEC Filing, EHAB, Enhabit